



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Published Online
February 25, 2021
[https://doi.org/10.1016/S0140-6736\(21\)00502-X](https://doi.org/10.1016/S0140-6736(21)00502-X)

For the CDC's guidelines for reopening schools see <https://www.cdc.gov/coronavirus/2019-ncov/community/schools-childcare/index.html>

of SARS-CoV-2 infection, it would be unwise to let the virus circulate in children, with consequent risk to their families. Reopening fully in the setting of high community transmission without appropriate safeguards risks depriving many children of education and social interaction again, worsening existing inequalities. By contributing to high community transmission, it also provides fertile ground for virus evolution and new variants.

Multi-layered mitigations can substantially reduce the risk of transmission within schools and into households.¹³ In the panel we summarise a set of recommendations that are in line with guidelines from the US Centers for Disease Control and Prevention (CDC) and practised in many countries to reduce the risk of transmission in schools and mitigate the impact of COVID-19 on children and families. A detailed set of recommendations and an infographic are provided in the appendix. Making schools safer goes hand in hand with reducing community transmission and is essential to allow schools to safely reopen and remain open.

NAA and PR were involved in SARS-CoV-2 saliva testing pilots in Southampton supported by the Department of Health and Social Care. NAA experienced long COVID symptoms. MM, SM, and SR are members of Independent SAGE. All other authors declare no competing interests.

**Deepti Gurdasani*, **Nisreen A Alwan*, *Trisha Greenhalgh*, *Zoë Hyde*, *Luke Johnson*, *Martin McKee*, *Susan Michie*, *Kimberly A Prather*, *Sarah D Rasmussen*, *Stephen Reicher*, *Paul Roderick*, *Hisham Ziauddeen*

d.gurdasani@qmul.ac.uk;

n.a.alwan@soton.ac.uk

William Harvey Research Institute, Queen Mary University of London, London E1 4NS, UK (DG); School of Primary Care, Population Sciences and Medical Education, University of Southampton, Southampton, UK (NAA, LJ, PR); Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK (TG); University of Western Australia, Perth, WA, Australia (ZH); London School of Hygiene & Tropical Medicine, London, UK (MM); University College London, London, UK (SM); University of California San Diego, San Diego, CA, USA (KAP); Department of Mathematics, University of Cambridge, Cambridge, UK (SDR); Institute for Advanced Study, Princeton University, Princeton, NJ,

USA (SDR); University of St Andrews, Edinburgh, UK (SR); Department of Psychiatry, University of Cambridge, Cambridge, UK (HZ)

- 1 Department for Education. Schools coronavirus (COVID-19) operational guidance. February, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/963541/Schools_coronavirus_operational_guidance.pdf (accessed March 4, 2021).
- 2 Department for Education. Week 47 2020. Attendance in education and early years settings during the coronavirus (COVID-19) outbreak. Nov 24, 2020. <https://explore-education-statistics.service.gov.uk/find-statistics/attendance-in-education-and-early-years-settings-during-the-coronavirus-covid-19-outbreak/2020-week-47> (accessed March 9, 2021).
- 3 Jeffreys B. More children in England missing school over Covid-19. Oct 27, 2020. <https://www.bbc.co.uk/news/education-54695618> (accessed March 9, 2021).
- 4 Hyde Z. COVID-19, children and schools: overlooked and at risk. *Med J Aust* 2021; **214**: 190–91.e1.
- 5 Hyde Z. Difference in SARS-CoV-2 attack rate between children and adults may reflect bias. *Clin Infect Dis* 2021; published online Feb 26. <https://doi.org/10.1093/cid/ciab183>.
- 6 Haug N, Geyrhofer L, Londei A, et al. Ranking the effectiveness of worldwide COVID-19 government interventions. *Nat Hum Behav* 2020; **4**: 1303–12.
- 7 Scientific Advisory Group for Emergencies. Children's Task and Finish Group: update to 4th Nov 2020 paper on children, schools and transmission. Dec 17, 2020. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/948617/s0998-tfc-update-to-4-november-2020-paper-on-children-schools-transmission.pdf (accessed March 4, 2021).
- 8 Volz E, Mishra S, Chand M, et al. Transmission of SARS-CoV-2 lineage B.1.1.7 in England: insights from linking epidemiological and genetic data. *MedRxiv* 2021; published online Jan 4. <https://www.medrxiv.org/content/10.1101/2020.12.30.20249034v2> (preprint).
- 9 Munday JD, Jarvis CI, Gimma A, et al. Estimating the impact of reopening schools on the reproduction number 2 of SARS-CoV-2 in England, using weekly contact survey data. *CMMID* 2021; published online Feb 15. <https://cmmid.github.io/topics/covid19/comix-schools.html> (preprint).
- 10 Scientific Pandemic Influenza Group on Modelling, Operational sub-group. Summary of further modelling. Feb 17, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/963565/S1130_SPI-M-O_Summary_of_further_modelling_of_easing_restrictions.pdf (accessed March 4, 2021).
- 11 Riley S, Walters CE, Wang H, et al. REACT-1 round 9 final report: continued but slowing decline of prevalence of SARS-CoV-2 during national lockdown in England in February 2021. *MedRxiv* 2021; published online March 6. <https://doi.org/10.1101/2021.03.03.21252856> (preprint).
- 12 Skytg24. Variante Covid, Corzano: focolaio in paese, chiuse le scuole. Feb 3, 2021. <https://tg24.sky.it/milano/2021/02/03/variante-covid-corzano-brescia> (accessed March 4, 2021).

- 13 Lessler J, Grabowski MK, Grantz KH, et al. Household COVID-19 risk and in-person schooling. *MedRxiv* 2021; published online March 1. <https://doi.org/10.1101/2021.02.27.21252597> (preprint).

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine

The rapid implementation of SARS-CoV-2 vaccination is now a global health-care priority. Successful phase 3 trial outcomes have been reported for numerous vaccines that induce robust humoral and cellular immune responses against the SARS-CoV-2 spike protein.^{1–6} To gain rapid control of accelerating cases and maximise public health impact, the UK Government has adopted the strategy of delaying second vaccination to 12 weeks. This policy has generated controversy, particularly among health-care workers (HCWs), the majority of whom have received BNT162b2 mRNA vaccine.⁷

Limited data on immune responses to single-dose vaccination with BNT162b2 are available, and vaccine responses following previous natural infection have not been assessed in clinical trials.^{2–6} We have therefore investigated immunological responses to single-dose BNT162b2 using a combination of serology, live virus neutralisation, and T-cell enzyme-linked immunospot (ELISpot) assays.

72 HCWs from Imperial College Healthcare NHS Trust, who were vaccinated between Dec 23 and Dec 31, 2020, provided blood samples at the time of receiving their first dose of BNT162b2 vaccine and 21–25 days after vaccination. Baseline samples were tested for antibodies to SARS-CoV-2 nucleocapsid and spike (anti-S) proteins using the Abbott Architect SARS-CoV-2 IgG and IgG Quant II, respectively

(Abbott, Maidenhead, UK). 21 (29%) participants had evidence of previous SARS-CoV-2 infection: 16 with positive baseline serology, and five further with strong T-cell responses to non-spike antigens post-vaccination (>100 spot forming units [SFU] per 10^6 peripheral blood mononuclear cells [PBMC]).


Although baseline ELISpot data were not available for these five participants, a cohort of 30 unvaccinated, infection-naïve participants did not demonstrate reactivity to these peptide pools. 51 participants had negative baseline serology and cellular responses post-vaccine limited to spike

antigens; this group was defined as infection-naïve.

As BNT162b2 mRNA encodes the spike glycoprotein of SARS-CoV-2, we assessed immune responses to spike protein post-vaccination. Anti-S titres were significantly higher in individuals with previous natural infection than in infection-naïve individuals (median 16 353 arbitrary units [AU] per mL [IQR 4741–28 581] vs 615.1 AU/mL [286.4–1491], $p < 0.0001$; figure A). The five participants with previous natural infection yet negative serology at baseline developed post-vaccination anti-S titres that were intermediate between the infection-naïve and

Figure: Immunological responses to a single dose of BNT162b2 mRNA vaccine

(A) Anti-S antibody titres 21–25 days after vaccination in individuals who were infection-naïve or had evidence of previous natural infection. Datapoints with open circles represent five individuals who, despite a negative serological test at baseline, were identified as having previous infection due to reactivity to non-spike peptides on ELISpot testing post-vaccination (which could not have been induced by vaccine alone). Dotted line indicates median anti-spike titre in a cohort of health-care workers 2–8 weeks after PCR-confirmed natural infection with SARS-CoV-2 ($n=23$, IQR 463–3621). (B) Correlation of post-vaccination anti-spike titre with age in infection-naïve participants. (C) SARS-CoV-2 live virus neutralising antibody titres in the eight individuals with paired results available ($n=4$ infection-naïve, $n=4$ with previous natural infection). (D) SARS-CoV-2 live virus neutralising antibody titres post-vaccination in infection-naïve individuals and individuals with previous infection. (E) T-cell responses to SARS-CoV-2 peptide pools post-vaccination in infection-naïve individuals and individuals with previous infection. Peptide pool 1 and peptide pool 2 contain spike protein peptides S1 and S2. Dotted lines indicate mean plus 3 standard deviation for each peptide pool calculated from infection naïve, unvaccinated individuals (48, 43, 26, 33, and 26 SFU/ 10^6 PBMC for peptide pools 1–5 respectively). (F) T-cell responses to spike protein peptides of SARS-CoV-2 post-vaccination in infection-naïve and previously infected participants. Inset shows example of ELISpot for an infection-naïve and a previously infected individual for the 2 spike peptide wells. Dotted line indicates mean plus 3 standard deviation for spike peptide pool reactivity calculated from infection naïve, unvaccinated individuals. All data are median with IQR. Statistical analysis was by Kruskal-Wallis test with Dunn's post-hoc correction (A), Spearman rank correlation (B) and Mann-Whitney test (D, F). SFU=spot forming unit. PBMC=peripheral blood mononuclear cells. NT₅₀=neutralisation titres that achieved 50% neutralisation.



previously infected groups (figure A). Infection-naïve individuals showed an inverse correlation between post-vaccination anti-S titre and age (figure B), with individuals older than 50 years generating a significantly weaker serological response than those younger than 50 years (median 230.1 AU/mL vs 888.9 AU/mL, $p < 0.0001$; figure A). This correlation was not seen in the group with previous natural infection (figure B).

Anti-S titre is reported to correlate with in-vitro virus neutralisation. We therefore used a subset of samples for live SARS-CoV-2 virus (SARS-CoV-2/England/IC19/2020) neutralisation assays on Vero cells.⁸ Eight paired sera ($n=4$ infection-naïve, $n=4$ previous natural infection) and a further 15 post-vaccination samples were included ($n=12$ infection-naïve, $n=3$ previous natural infection). In individuals with previous exposure, vaccine induced very strong neutralising antibody titres even in those without detectable or very low virus neutralisation titres (NT) at baseline (median NT₅₀ 1/1635, range 1/1123.1 to beyond the 1/2560 upper limit; figure C, D). In infection-naïve individuals, vaccination induced detectable neutralising antibodies in 15 of 16 sera, but titres were all lower than for previously infected individuals (median NT₅₀ 1/29.50, range from below lower limit of detection to 1/68; figure C, D).

We next assessed post-vaccination T-cell responses using the T-SPOT Discovery SARS-CoV-2 (Oxford Immunotec, Oxford, UK), which includes a panel of five SARS-CoV-2 peptide pools. Post-vaccination, participants with evidence of previous SARS-CoV-2 infection at baseline ($n=21$) mounted very strong T-cell responses to spike peptides (median 400 SFU/10⁶ PBMC [IQR 287–544]; figure E, F). In the infection-naïve group, post-vaccination T-cell responses to spike peptides were significantly weaker than in individuals with previous infection

(38 SFU/10⁶ PBMC [IQR 26–110], $p < 0.0001$; figure E, F), and 24 (50%) of 48 participants generated T-cell responses that could be considered negative (< 40 SFU/10⁶ PBMC). Unlike humoral responses, there was no correlation between age and degree of T-cell response.

In summary, we show that individuals with previous SARS-CoV-2 infection generate strong humoral and cellular responses to one dose of BNT162b2 vaccine, with evidence of high titres of in-vitro live virus neutralisation. In contrast, most individuals who are infection-naïve generate both weak T-cell responses and low titres of neutralising antibodies.

Existing studies predicting risk of re-infection based on neutralising antibody titres, or longevity of immunological responses, are highly heterogeneous.^{9–13} Evidence for the longevity and protective effect of T-cell responses is particularly limited. In particular, peptide pool selection might affect T-cell responses, meaning results cannot be compared between studies. We use S1 and S2 peptide pools, rather than peptides spanning the whole spike glycoprotein, which might underestimate the true magnitude of T-cell responses. Despite the difficulty of extrapolating immunological data to clinical protection, our findings raise important issues that warrant consideration when determining optimal use of vaccine supplies. Firstly, those with serological evidence of previous disease at baseline mount robust antibody and T-cell responses after a single dose of vaccine. Conversely, some infection-naïve individuals mount very little demonstrable response to single-dose vaccination, which might not provide sufficient immunity to protect from clinical disease or viral shedding, and might not persist for a 12-week delay until second vaccine is administered. One infection-naïve individual included in our study developed symptomatic, PCR-proven

infection 5 weeks after one dose of vaccine; notably, their anti-S titre post-vaccination was 61.8 AU/mL.

In keeping with published reports of other vaccines, serological response to BNT162b2 inversely correlates with age.¹⁴ We found median anti-S titres post-vaccination in the infection-naïve cohort to be lower than those seen 2–8 weeks after natural infection alone, and this difference was particularly striking in those older than 50 years. Two participants did not seroconvert, and eight participants generated antibody titres less than 250 AU/mL, which might not be sufficient for any virus neutralisation based on correlation of virus neutralisation and anti-S titre in our study. All ten of these individuals were older than 50 years. In a setting where prioritisation of groups of HCWs for second vaccination might be necessary, consideration must be given to protocolised vaccination of infection-naïve individuals or those over the age of 50 (who are at increased risk of both severe COVID-19 and minimal vaccine response). These results also highlight the need for continuing rigorous use of personal protective equipment after vaccination to prevent both infection and asymptomatic spread of disease.

MP, CC, PK, and MW contributed equally. PK and MW have received support to use the T-SPOT Discovery SARS-CoV-2 from Oxford Immunotec. X-NX and PK are supported by the Department for International Development and the Wellcome Trust. MP is supported by the National Institute for Health Research (NIHR). All other authors declare no competing interests. We thank the HCWs who participated in this study. We also thank Graham Pickard and Donald Mokri for help with the spike protein antibody assay. We acknowledge support from the NIHR Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London.

**Maria Prendecki, Candice Clarke, Jonathan Brown, Alison Cox, Sarah Gleeson, Mary Guckian, Paul Randell, Alessia Dalla Pria, Liz Lightstone, Xiao-Ning Xu, Wendy Barclay, Stephen P McAdoe, Peter Kelleher, Michelle Willicombe*
m.prendecki@imperial.ac.uk

Centre for Inflammatory Disease, Department of Immunology and Inflammation (MP, CC, LL, SPM, MW) and Department of Infectious Diseases (JB, ADP, X-NX, WB, PK), Imperial College London, London W12 0NN, UK; Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK (MP, CC, SG, LL, SPM, MW); Department of Infection and Immunity North West London Pathology NHS Trust, London, UK (AC, MG, PR, PK); Department of HIV and Genitourinary Medicine, Chelsea and Westminster Hospital, London, UK (ADP, PK)

- Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *New Eng J Med* 2020; **383**: 2603–15.
- Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. *New Eng J Med* 2020; **383**: 2439–50.
- Ewer KJ, Barrett JR, Belij-Rammerstorfer S, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. *Nature Med* 2020; **27**: 270–78.
- Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *New Eng J Med* 2021; **384**: 403–16.
- Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet* 2021; **397**: 99–111.
- Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. *medRxiv* 2020; published online Dec 11. <https://doi.org/10.1101/2020.12.09.20245175> (preprint).
- Mahase E. Covid-19: medical community split over vaccine interval policy as WHO recommends six weeks. *BMJ* 2021; **372**: n226.
- McKay PF, Hu K, Blakney AK, et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. *Nature Comm* 2020; **11**: 3523.
- Deng W, Bao L, Liu J, et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. *Science* 2020; **369**: 818–23.
- Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. *Nature Microbiol* 2020; **5**: 1598–607.
- Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science* 2020; **370**: 1227–30.
- Wyllie D, Mulchandani R, Jones HE, et al. SARS-CoV-2 responsive T cell numbers are associated with protection from COVID-19: a prospective cohort study in keyworkers. *medRxiv* 2020; published online Nov 4. <https://doi.org/10.1101/2020.11.02.20222778> (preprint).
- Chandrashekar A, Liu J, Martinot AJ, et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. *Science* 2020; **369**: 812–17.
- Zimmermann P, Curtis N. Factors that influence the immune response to vaccination. *Clin Microbiol Rev* 2019; **32**: e00084-18.

COVID-19, cults, and the anti-vax movement

Rochelle Burgess and colleagues¹ eloquently described participatory community engagement as essential for successful COVID-19 vaccination, which involves appreciating the heterogeneous public and working with communities and their leaders to enable bottom-up approaches. They suggested that COVID-19 has drawn attention to the structural violence that is embedded within society, with the pandemic furthering the marginalisation of historically oppressed and excluded groups. Burgess and colleagues¹ drew attention to how people who might have suffered disproportionate economic and health consequences from COVID-19 are now being asked “to trust the same structures”¹ that failed to provide adequate resources and social protection during the pandemic. Failure to address these contextual dimensions can worsen mistrust, damaging vaccine uptake. However, Burgess and colleagues make a distinction between “people wholly opposed to vaccinations (anti-vaxxers) and...vaccine hesitancy”¹, and imply participatory community engagement as a means to engage only people with vaccine hesitancy.

Lessons from studying cults (which are less pejoratively called new religious movements, describing movements that emerged in the late 20th century) can inform approaches to the anti-vax movement. A cult has come to mean a non-conforming ideology, or a religion that is disliked, with beliefs that are unacceptable to mainstream society. Just as cults are grouped together as sinister, bad, or wrong, the discourse surrounding anti-vaxxers in both academic and popular circles can be dismissive and derogatory. The pejorative label and negative attitudes towards cults promote an us-and-them viewpoint, creating martyrs^{2,3} and extending the length of time that members hold the new beliefs, thus encouraging further involvement in the movement and radicalisation.⁴

Learning from these consequences, a more constructive perspective could view the anti-vax movement as a religious phenomenon, involving a whole spectrum of ideas, and focus on the essential need to understand the beliefs that are involved to avoid further marginalisation. Hence, implying that anti-vaxxers are beyond the reach of community engagement activities could result in increased anti-vax activities. We suggest a more inclusive approach, where the same inquisitive dialogue and contextual understanding that was suggested for vaccine hesitancy should be extended to members of the anti-vax movement.

SM declares funding by the Economic and Social Research Council and the Parkes Foundation towards the cost of her doctoral study. CH declares no competing interests.

*Sophie Mylan, Charlotte Hardman
sophie.mylan@lshtm.ac.uk

Department of Global Health and Development, London School of Hygiene & Tropical Medicine, London WC1H 9SH, UK (SM); National Health Service, London, UK (SM); Department of Theology and Religion, Durham University, Durham, UK (CH)

- Burgess RA, Osborne RH, Yongabi KA, et al. The COVID-19 vaccine rush: participatory community engagement matters more than ever. *Lancet* 2021; **397**: 8–10.
- van Twist A, van Eck D, Newcombe S. “Trust me, you can’t trust them”: stigmatised knowledge in cults and conspiracies. In: Dyrendal A, Robertson DG, Asprey E, eds. *Handbook of conspiracy theory and contemporary religion*. Leiden: Brill Academic Publishers, 2018: 152–79.
- Singler B. Big, bad pharma: the indigo child concept and biomedical conspiracy theories. *Nova Relig* 2015; **19**: 17–29.
- Barker E. *New religious movements: a practical introduction*. London: Her Majesty’s Stationery Office, 1989.

Health systems in the ACT-A

The attention to health systems in the headline of Ann Usher’s World Report¹ about the Access to COVID-19 Tools Accelerator (ACT-A) is most welcome. However, we were disappointed that the World Report focused on medical oxygen and personal protective equipment (PPE), interventions that, although important, are better described as components of clinical



Indrani Mukherjee/Getty Images